Senior insider sale
Chief Financial Officer at ULTRAGENYX PHARMACEUTICAL INC. — senior position signals high conviction
$514.5K
22.47K shares
HORN HOWARD plans to sell 22.47K shares of ULTRAGENYX PHARMACEUTICAL INC. valued at approximately $514.5K. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Performance Shares
Not Applicable
Restricted Stock
Not Applicable
Restricted Stock
Not Applicable
Restricted Stock
Not Applicable
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
3/1/2026 | Performance Shares Not Applicable | 658.00 | — |
3/1/2026 | Restricted Stock Not Applicable | 939.00 | — |
10/9/2025 | Restricted Stock Not Applicable | 1.34K | — |
10/9/2024 | Restricted Stock Not Applicable | 1.74K | — |
| Total | 4.68K | ||
Completed
Units to sell
4.68K
Market value
$98.2K
Units to sell
1.64K
Market value
$36.6K
Units to sell
5.29K
Market value
$120.6K
Units to sell
3.12K
Market value
$70.3K
Units to sell
3.06K
Market value
$72.1K
Planned — Approximate Date
Units to sell
4.68K
Market value
$116.6K
Units
22.47K
Value
$514.5K
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
4/1/2026 | 4.68K | $98.2K | — | Completed |
3/3/2026 | 1.64K | $36.6K | — | Completed |
3/2/2026 | 5.29K | $120.6K | — | Completed |
3/2/2026 | 3.12K | $70.3K | — | Completed |
2/2/2026 | 3.06K | $72.1K | — | Completed |
| Planned — Approximate Date | ||||
5/1/2026 | 4.68K | $116.6K | NASDAQ | Planned |
| Total | 22.47K | $514.5K | ||